Brief: Sorrento Therapeutics Inc - On Feb 13, Co, Unit Scintilla Pharmaceuticals, Commenced Voluntary Proceedings Under Chapter 11 Of U.S. Bankruptcy Code

Sorrento Therapeutics

13/02/2023 11:24

Feb 13 (Reuters) - Sorrento Therapeutics Inc  SRNE.O :
    * SORRENTO THERAPEUTICS INC -  ON FEB 13, CO, UNIT SCINTILLA
PHARMACEUTICALS, COMMENCED VOLUNTARY PROCEEDINGS UNDER CHAPTER
11 OF U.S.  BANKRUPTCY CODE
    * SORRENTO THERAPEUTICS- DEBTORS HAVE REQUESTED CHAPTER 11
PROCEEDINGS BE JOINTLY ADMINISTERED UNDER CAPTION IN RE SORRENTO
THERAPEUTICS, INC., ET AL.
    * SORRENTO THERAPEUTICS - DEBTORS CONTINUE TO OPERATE
BUSINESS IN
ACCORDANCE WITH APPLICABLE PROVISIONS OF BANKRUPTCY CODE, ORDERS
OF BANKRUPTCY COURT
    * SORRENTO THERAPEUTICS INC - DEBTORS INTEND TO SEEK
APPROVAL OF A
VARIETY OF “FIRST DAY” MOTIONS

Further company coverage:  SRNE.O 
 ((Reuters.Briefs@thomsonreuters.com;;))